Plus   Neg

Pharmacyclics Inc. (PCYC) Leaped To A New High After NDA Submission

Pharmacyclics Inc. (PCYC) announced Wednesday morning that it has submitted a New Drug Application to the FDA for the investigational oral Bruton's tyrosine kinase inhibitor, ibrutinib, for two relapsed/refractory B-cell malignancy indications: mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma.

Pharmacyclics gapped up Wednesday and climbed sharply during the first hour of trade. The stock ended the day with a gain of 10.74 at $100.26 on above average volume. Pharmacyclics surged past resistance and set a new high for the year.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

comments powered by Disqus
Follow RTT